ERBB2 and gastroesophageal junction adenocarcinoma: Apatinib improved median progression-free survival for 26 months and OS for 6.5 months versus placebo in Chinese patients with advanced gastric or gastroesophageal junction adenocarcinoma in the third line and beyond.[34] Disitamab vedotin has been approved in China for the treatment of advanced or metastatic G/GEJ adenocarcinoma patients with overexpression of HER2, and has shown efficacy in our second and third line treatments.